

Please try another search
Symbol | Exchange | Currency | ||
---|---|---|---|---|
BIIB | NASDAQ | USD | Real-time | |
BIIB | Mexico | MXN | Delayed | |
BIIB | Frankfurt | EUR | Delayed | |
BIIB | Xetra | EUR | Delayed | |
BIIB | TradeGate | EUR | Delayed | |
BIIB | Santiago | USD | Delayed | |
BIIB | Buenos Aires | ARS | Delayed | |
BIIB34 | BM&FBovespa | BRL | Delayed | |
BIIB | Vienna | EUR | Delayed |
(Reuters) - Biogen Inc (NASDAQ:BIIB) said on Monday its research chief Alfred Sandrock, who led development of its Alzheimer's disease drug Aduhelm, is leaving the company after a 23-year run. The...
By Andrea Shalal and Ahmed Aboulenein WASHINGTON (Reuters) - President Joe Biden on Friday said he would nominate Robert Califf for a second stint as commissioner of the U.S. Food and Drug...
By Peter Nurse Investing.com -- Stocks in focus in premarket trade on Friday, November 12th. Please refresh for updates. Johnson & Johnson (NYSE:JNJ) stock rose 2.8% after the company said it will...
By Deena Beasley (Reuters) - Roche Holding AG (OTC:RHHVF), still months away from seeking regulatory approval of its experimental Alzheimer's drug, is already taking aim at rival Biogen Inc...
By Sam Boughedda Investing.com — Barring a reversal, Biogen Inc (NASDAQ:BIIB) stock is set to close down for the third consecutive day after it was reported that the company is investigating the death...
The healthcare industry has gained substantially since the onset of the COVID-19 pandemic. With the continuing spread of the virus, and an aging population, the demand for healthcare services is...
By Manojna Maddipatla and Mrinalika Roy (Reuters) -Eli Lilly said on Tuesday it has started the application process for a U.S. approval of its closely watched experimental Alzheimer's drug and...
Mizuho Securities analyst Salim Syed maintained a Hold rating on Biogen (NASDAQ:BIIB) on Tuesday, setting a price target of $270, which is approximately 0.02% above the present share price of...
The economy is in recovery mode with the rapid roll-out of vaccines. A solid start to the third-quarter earnings season, a decline in the initial jobless claims, and declining COVID-19 cases are...
By Sam Boughedda Investing.com — Several analysts cut their price targets on Biogen Inc's (NASDAQ:BIIB) shares after concerns about Aduhelm sales following the company's third quarter earnings...
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review